Numerof Consultant Christopher de Wolff led a session entitled Reimbursement Considerations for Early-Stage Companies at the 2014 BIO International Convention on June 24.  Executives from Aerial BioPharma, RiverVest Venture Partners, and Bayer joined Christopher in sharing perspectives on the need for data-based evidence to support product value, and considerations for early-stage pharma companies conducting their own research before bringing in potential investors.

For more information about the conference and Christopher’s panel, click here.